A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes

Summary

This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2 diabetes. Approximately 20 clinical sites may be utilized in the United States so that approximately 300 subjects (a potential 20% screening failure rate) may be screened for total 28-week study period (2 weeks for screening, 24 weeks for treatment, and 2 weeks for safety follow-up).

Timeline

Start

2018-06-18

Primary completion

2019-06-25

Completion

2019-07-15

Drugs

Indications